Lithium carbonate (Lithobid, Eskalith) is the gold-standard mood stabilizer used to treat acute manic episodes in bipolar I disorder and to prevent future manic and depressive episodes long-term. Its mechanism involves inhibition of GSK-3Ξ² and inositol monophosphatase, modulating serotonin and norepinephrine neurotransmission and promoting neuroprotection. Common side effects include fine hand tremor, polyuria, weight gain, and nausea. It has a dangerously narrow therapeutic index β blood levels must be monitored regularly, as toxicity (confusion, coarse tremor, ataxia, seizures) can occur at levels only slightly above the therapeutic range and constitutes a medical emergency.
Lithium Carbonate
Lithium is a naturally occurring alkali metal that has been used as a psychiatric medication since the 1940s. It remains the gold-standard mood stabilizer for bipolar disorder and one of the most effective agents for reducing the risk of suicide in mood disorders. Its narrow therapeutic index makes monitoring essential.
Uses & FDA Indications
Lithium has been in clinical use for over 70 years and carries robust evidence for bipolar disorder treatment and prevention. It also has an unparalleled evidence base for suicide risk reduction.
FDA-Approved Uses
- Bipolar I disorder, acute manic episodes β treatment of active mania in adults
- Bipolar disorder, maintenance β prevention of future manic and depressive episodes
Off-Label Uses
- Bipolar depression (adjunctive)
- Augmentation of antidepressants in treatment-resistant depression
- Cluster headache prophylaxis
- Suicide risk reduction in mood disorders
- Schizoaffective disorder
How It Works
The precise mechanism of lithium's mood-stabilizing effects is not fully understood, but several key pathways have been identified. Lithium inhibits glycogen synthase kinase-3 (GSK-3Ξ²), an enzyme involved in intracellular signaling that plays a role in neuronal plasticity, apoptosis, and circadian rhythms. It also inhibits inositol monophosphatase, depleting inositol and modulating phosphatidylinositol signaling cascades critical to neurotransmitter receptor function.
Lithium modulates serotonin neurotransmission, increasing presynaptic release, and affects norepinephrine turnover. It also has neuroprotective properties, promoting BDNF (brain-derived neurotrophic factor) expression and reducing neuronal apoptosis, which may explain some of its long-term benefits in mood disorder prevention.
Lithium is renally excreted and competes with sodium in the kidney. Conditions that reduce sodium (dehydration, low-salt diets, diuretics) cause the kidney to reabsorb more lithium, increasing levels and toxicity risk.
Side Effects
Common
- Fine hand tremor (most common; often dose-related)
- Polyuria and polydipsia (increased urination and thirst)
- Nausea, diarrhea, vomiting β often at the start of therapy
- Weight gain
- Cognitive dulling or mild memory impairment
- Acne and psoriasis exacerbation
- Hypothyroidism (occurs in up to 40% of long-term users)
- Edema
Serious
- Lithium toxicity β signs include coarse tremor, confusion, ataxia, seizures, cardiac arrhythmia; can be fatal
- Nephrogenic diabetes insipidus β impaired urinary concentration; occurs with long-term use
- Chronic kidney disease β long-term use associated with structural kidney changes; regular renal function monitoring is essential
- Cardiac conduction abnormalities β T-wave changes; rare arrhythmias
- Ebstein's anomaly β cardiac malformation risk if used in first trimester of pregnancy (risk is small but real)
NARROW THERAPEUTIC INDEX: Lithium toxicity can occur even at levels slightly above the therapeutic range. Symptoms of toxicity include coarse tremor, drowsiness, confusion, vomiting, and ataxia. Severe toxicity can cause seizures, cardiac arrhythmia, coma, and death. Regular blood level monitoring is mandatory. Call Poison Control (1-800-222-1222) immediately if toxicity is suspected.
Drug Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| NSAIDs (ibuprofen, naproxen, indomethacin) | Reduce renal lithium clearance by inhibiting prostaglandin-mediated effects on tubular function; increase lithium levels by 25β60% | High β avoid or use with extreme caution; use acetaminophen instead |
| Thiazide diuretics (hydrochlorothiazide) | Increase lithium reabsorption in the proximal tubule due to sodium depletion; can cause toxicity | High β avoid; if necessary, reduce lithium and monitor levels closely |
| ACE inhibitors / ARBs (lisinopril, losartan) | Reduce renal lithium excretion, raising levels significantly | High β combination requires careful monitoring; dose adjustment often needed |
| Haloperidol and antipsychotics | Rare reports of irreversible neurotoxicity; additive risk of QT prolongation | Moderate β monitor for neurological symptoms; combination is widely used but requires vigilance |
| SSRIs / SNRIs | Risk of serotonin syndrome with combination; lithium may enhance serotonergic effects | Moderate β generally used together safely but monitor for serotonergic symptoms |
| Caffeine | Increases renal lithium clearance; reducing caffeine intake may raise lithium levels | LowβModerate β advise patients to maintain consistent caffeine intake |
| Sodium (dietary) | Low-sodium diet decreases renal lithium clearance, raising blood levels; high-sodium diet does the opposite | High β patients should maintain consistent salt intake and avoid dehydration |
Warnings & Contraindications
Lithium is contraindicated in patients with severe renal impairment, significant cardiovascular disease, severe debilitation or dehydration, and in those receiving diuretics who cannot be closely monitored. Renal and thyroid function must be assessed before starting and monitored regularly throughout treatment.
Key Precautions
- Dehydration and fever: Even mild dehydration (illness, hot weather, exercise) can raise lithium levels to toxic range; patients must maintain adequate fluid and salt intake
- Renal monitoring: Serum creatinine and eGFR should be checked regularly; kidney function declines in some long-term users
- Thyroid monitoring: TSH should be checked at baseline and at least annually; hypothyroidism can be treated with levothyroxine without stopping lithium
- Pregnancy: Risk of Ebstein's anomaly in first trimester; careful risk-benefit discussion required; neonatal lithium toxicity risk at delivery
- Elderly patients: Reduced renal clearance increases toxicity risk; use with extra caution and close monitoring
Frequently Asked Questions
How often do lithium blood levels need to be checked?
Blood level monitoring is a core part of lithium therapy. Levels are typically checked frequently when starting or adjusting therapy to establish the correct range for the individual patient, then less often once stable β typically every 3 to 6 months for long-term users. Levels should also be checked any time symptoms of toxicity appear, after illness causing dehydration, or when other medications are changed.
What are the early signs of lithium toxicity?
Early signs include a coarser tremor than usual (the normal tremor is fine), nausea and diarrhea, drowsiness, confusion, slurred speech, and muscle twitching. If any of these appear, patients should stop lithium and seek medical attention immediately. Poison Control (1-800-222-1222) can also provide guidance. Toxicity is a medical emergency at its more severe stages.
Does lithium permanently damage the kidneys?
Long-term lithium use is associated with structural kidney changes and a modest decline in glomerular filtration rate in some patients. The risk of clinically significant chronic kidney disease increases with duration of use, higher blood levels, and episodes of acute toxicity. Regular monitoring allows early detection of kidney changes and informed treatment decisions. Many patients take lithium safely for decades without significant kidney problems.
Can lithium be used during pregnancy?
Lithium is classified as Category D due to a small but established risk of Ebstein's anomaly (a cardiac malformation) with first-trimester exposure. However, the absolute risk is low, and untreated bipolar disorder carries its own serious risks during pregnancy. The decision to continue or stop lithium during pregnancy should be made collaboratively between patient and clinician, with maternal-fetal medicine consultation as needed.
Need to identify a pill? Use the PillID visual search tool.
Identify a Pill β